You are here: Industry Insights > biosimilar

News List

Sandoz receives US FDA approval for biosimilar Hyrimoz biospectrum
November 05, 2018
Hyrimoz is third FDA-approved Sandoz biosimilar in US
Sales of Roche’s Rituxan Have Started to Decline as Biosimilars Thereof are Marketed 1℃
November 02, 2018
Celltrion and Teva Pharmaceutical released big news on October 11, 2018 that the Rituxan® (rituximab) biosimilar. After the marketing, CT-P10 will become the first Rituxan® (rituximab) biosimilar approved for marketing in the U.S.
JHL Biotech receives China approval for cancer Biosimilar biospectrumasia
October 19, 2018
The proposed bevacizumab biosimilar, JHL1149, treats several forms of cancer, including advanced non-squamous non-small-cell lung cancer (NSCLC), metastatic colorectal cancer, metastatic kidney cancer, advanced cervical cancer and recurrent ovarian cancer
Another Humira biosimilar hits EU shores pharmatimes
October 19, 2018
Samsung Bioepis has announced the European launch of Humira biosimilar Imraldi, as NHS chiefs tell Trusts to ensure they are ready to realise the potential savings from using cheaper versions of the world’s biggest selling drug.
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access worldpharmanews
October 15, 2018
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humi
FDA panel unanimously backs Celltrion's Rituxan biosimilar fiercepharma
October 11, 2018
Celltrion and its biosimilar marketing partner Teva may be on their way to challenging Roche’s top drug, Rituxan.
EU green light for new Humira biosimilar pharmatimes
September 21, 2018
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.
Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts biopharmadive
September 20, 2018
The importance of Mylan's copycat extends well beyond the bottom lines of the two drugmakers directly involved. Leerink analyst Geoffrey Porges called it "the latest battle" in the space that "will set the industry tone for biosimilar adoption in the near
China accepts first application for Humira biosimilar biospectrumasia
September 05, 2018
Bio-Thera Solutions is developing several additional proposed biosimilars, including a biosimilar version of Avastin, which is currently being evaluated in a global Phase III clinical trial
JHL Biotech Gets Positive CHMP Scientific Advice for Bevacizumab Biosimilar biospectrumasia
August 13, 2018
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page